Skip to the page

Data / Drug companies / Aci Healthcare USA, Inc.

Aci Healthcare USA, Inc.: 10 products in the FDA NDC directory, labeler code 71093

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Aci Healthcare USA, Inc. (labeler code 71093) lists 10 products in the FDA National Drug Code Directory, covering 3 finished drugs by generic name. By type: 10 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 24, 2020.

The request: Watch Aci Healthcare USA, Inc. (FDA labeler code 71093): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
71093
Products in commercial distribution
10
Packages
16
Finished drugs by generic name
3
Prescription products
10
Over the counter products
0
Controlled substance products
Schedule IV 2
Flagged as original packager
10 of 10 products that carry the flag
Started marketing in the last 12 months
0
Earliest marketing start
November 29, 2017
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)10100%

Products by type

TypeProductsShare
Prescription drugs10100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

DrugProductsCompanies listing it
Quetiapine530
Metformin hydrochloride379
Zolpidem tartrate238

Dosage forms

Dosage formProductsShare
Tablet, film coated, extended release550%
Tablet550%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Zolpidem71093-156TabletGeneric drugs (ANDA)September 24, 2020
Zolpidem71093-155TabletGeneric drugs (ANDA)September 24, 2020
Metformin hydrochloride71093-134TabletGeneric drugs (ANDA)January 15, 2018
Metformin hydrochloride71093-133TabletGeneric drugs (ANDA)January 15, 2018
Metformin hydrochloride71093-132TabletGeneric drugs (ANDA)January 15, 2018
Quetiapine Extended Release71093-139Tablet, film coated, extended releaseGeneric drugs (ANDA)November 29, 2017
Quetiapine Extended Release71093-138Tablet, film coated, extended releaseGeneric drugs (ANDA)November 29, 2017
Quetiapine Extended Release71093-137Tablet, film coated, extended releaseGeneric drugs (ANDA)November 29, 2017
Quetiapine Extended Release71093-136Tablet, film coated, extended releaseGeneric drugs (ANDA)November 29, 2017
Quetiapine Extended Release71093-135Tablet, film coated, extended releaseGeneric drugs (ANDA)November 29, 2017

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.